SQUAWK/NEWS
Account
Account
Menu
Live News EQUITY FLASH H impact

VSTM: Reports Encouraging VS-7375 Data

Verastem Oncology reports encouraging clinical activity and favorable safety profile for VS-7375 in Phase 1/2 clinical study

VSTM

This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.